<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HB3008BD9382A46CE89C7D26F93AB0492" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 909 IH: Andrea Sloan CURE Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-02-12</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress>114th CONGRESS</congress>
<session>1st Session</session>
<legis-num>H. R. 909</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20150212">February 12, 2015</action-date> 
<action-desc><sponsor name-id="M001157">Mr. McCaul</sponsor> (for himself, <cosponsor name-id="B001251">Mr. Butterfield</cosponsor>, <cosponsor name-id="B001248">Mr. Burgess</cosponsor>, <cosponsor name-id="G000568">Mr. Griffith</cosponsor>, <cosponsor name-id="M001163">Ms. Matsui</cosponsor>, and <cosponsor name-id="L000567">Mr. Lance</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To amend the Federal Food, Drug, and Cosmetic Act with respect to expanding access for breakthrough drugs, and for other purposes.</official-title> 
</form> 
<legis-body id="H1E2310DB2E4E479EA41E983A30E9554E" style="OLC"> 
<section id="H72454617810D42C59828E4BCB4DA3B6A" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Andrea Sloan Compassionate Use Reform and Enhancement Act</short-title></quote> or the <quote>Andrea Sloan CURE Act</quote>.</text></section> <section id="HB0458148597A4B288835186A697CCF9F"><enum>2.</enum><header>Expanded access policy as condition of expedited approval</header><text display-inline="no-display-inline">Section 561 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref>) is amended—</text> 
<paragraph id="H8146F90B1EE44BF3BAE4A2A109E1698E"><enum>(1)</enum><text>by redesignating subsections (d) and (e) as subsections (e) and (f), respectively; and</text></paragraph> <paragraph id="HAAAE991367F44E9785201C1FE205B13C"><enum>(2)</enum><text>by inserting after subsection (c) the following new subsection:</text> 
<quoted-block id="H682CECEA512B42E9B3EA8044BF808F0B" style="OLC"> 
<subsection id="H5B65B2625B9145A996D46151458739CA"><enum>(d)</enum><header>Expanded access policy required for covered investigational drugs</header> 
<paragraph id="H4276DFF62D2E44D69D191A02CE5FF7DD"><enum>(1)</enum><header>In general</header><text>With respect to a covered investigational drug, not later than 30 days after the date on which the drug meets the definition of a covered investigational drug (as specified in paragraph (2)), the sponsor of the covered investigational drug shall submit to the Secretary, and make publicly available, the policy of the sponsor with respect to requests submitted under subsection (b). In the case of such a policy under which the sponsor accepts such requests, such policy shall include—</text> <subparagraph id="H23F745206F5F4F5AB1E609642EDDCB51"><enum>(A)</enum><text>a single point of contact who receives and processes such requests;</text></subparagraph> 
<subparagraph id="H0FDAE2E36AB74675B3FC90CDC4EAB72F"><enum>(B)</enum><text>procedures for making such requests;</text></subparagraph> <subparagraph id="HC775DDE350BA4CDD822BCEEB2FFEAAAA"><enum>(C)</enum><text>the general criteria for the sponsor’s consideration or approval of such requests; and</text></subparagraph> 
<subparagraph id="HE94D372147A54CBFAA72FE3AABBC92DC"><enum>(D)</enum><text>the amount of time the sponsor anticipates will be necessary to respond to such requests.</text></subparagraph></paragraph> <paragraph id="HA848EA4DD9B5427980DE49AB99E84CD9"><enum>(2)</enum><header>Covered investigational drug</header><text>In this subsection, the term <quote>covered investigational drug</quote> means a drug that—</text> 
<subparagraph id="H15675B9496454C83956C93E0C3097507"><enum>(A)</enum><text>is designated as a breakthrough therapy or as a fast track product;</text></subparagraph> <subparagraph id="H6ED10B8C0E0F4A10BFE3F7511FFF4245"><enum>(B)</enum><text>is designated under section 505E(d) as a qualified infectious disease product; or</text></subparagraph> 
<subparagraph id="HDD279BEE4BD54E99AF8920C1810B86B3"><enum>(C)</enum><text display-inline="yes-display-inline">is designated under section 526 as a drug for a rare disease or condition.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section> <section id="H9FD00B81D3A64214A35FFFC917F3BC69"><enum>3.</enum><header>Notification of submitters of expanded access requests</header><text display-inline="no-display-inline">Section 561 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref>), as amended by section 2, is further amended—</text> 
<paragraph id="H8670B30B7E744DF6B3C98313FD905D5D"><enum>(1)</enum><text>by redesignating subsections (e) and (f) (as redesignated by section 2(1)) as subsections (f) and (g), respectively; and</text></paragraph> <paragraph id="H4486073E7ACF48C7982740401F09BE64"><enum>(2)</enum><text>by inserting after subsection (d) (as inserted by section 2(2)) the following new subsection:</text> 
<quoted-block id="HC3B37FBD4AE141829E7AC13F19FAE13A" style="OLC"> 
<subsection id="HD7E3220AE97F4953B3467C5635CE3272"><enum>(e)</enum><header>Notification of submitters of requests</header><text>In the case of the denial by a manufacturer or distributor of a request under subsection (b), not later than 5 days after the date of such denial, the manufacturer or distributor, as applicable, shall submit to the person (or physician) who made the request written notice of the denial, including an explanation for the denial.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section> <section id="HB705D25A8591440CBDAAD0EBE13D60EC"><enum>4.</enum><header>Gao qualitative analysis on individual patient access to unapproved therapies and diagnostics</header><text display-inline="no-display-inline">Not later than 180 days after the date of the enactment of this Act and every two years thereafter through 2023, the Comptroller General of the United States shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor and Pensions of the Senate a report containing a qualitative analysis of the extent to which individual patients have access to investigational drugs pursuant to subsection (b) of section 561 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref>) and recommendations for improving such access. In preparing such report, the Comptroller General shall conduct a qualitative analysis of the following:</text> 
<paragraph id="HA29D8DA7DF0046E795C5E89E8AFC5B61"><enum>(1)</enum><text>Whether there are any identifiable patterns in requests submitted under subsection (b) of such section, such as the types of indications for which requests for individual patient access are sought or the reasons for the denial of such requests.</text></paragraph> <paragraph id="HF1BBB8F4ACAD4FC58CF279E96B0606B9"><enum>(2)</enum><text>What the primary barriers are to drug sponsors granting requests for individual patient access.</text></paragraph> 
<paragraph id="HBDCC9B5B23C94A9CB096F4DD20A6C555"><enum>(3)</enum><text>How the Secretary evaluates safety and efficacy data submitted in connection with such requests.</text></paragraph> <paragraph id="HF0E39BC5B1494242A8DA3A30281167BA"><enum>(4)</enum><text>The amount of time that—</text> 
<subparagraph id="H551D96445D5A49569C05A3697912C47C"><enum>(A)</enum><text>a physician typically takes to complete the paperwork necessary to make such a request;</text></subparagraph> <subparagraph id="H61BB8AE632BA4ED0839BF44DA24D2F24"><enum>(B)</enum><text>a drug sponsor takes to process such a request and to issue a decision with respect to the request; and</text></subparagraph> 
<subparagraph id="H2729D74C2A544634BEC920A82AB5F496"><enum>(C)</enum><text>the Secretary takes to process such a request and to issue a decision with respect to the request.</text></subparagraph></paragraph> <paragraph id="H3E47B016323640A890F6161640874D91"><enum>(5)</enum><text>How regulations, guidance, policies, or practices may be modified, streamlined, expanded, or discontinued to reduce or prevent delays in approving such requests.</text></paragraph> 
<paragraph id="H9D4EFDE2E489428CA5C2C5FE84ED2638"><enum>(6)</enum><text>The number of such requests that, for the period covered by the report—</text> <subparagraph id="H6EB59C06D7D947B78C70121909E9FAE4"><enum>(A)</enum><text>were approved by drug sponsors and the Food and Drug Administration;</text></subparagraph> 
<subparagraph id="H3B9965A043BF408EA9AD555312889BBC"><enum>(B)</enum><text>were approved by drug sponsors but denied by the Food and Drug Administration; and</text></subparagraph> <subparagraph id="H157322A8519F45EA983B2DC04A18CFC4"><enum>(C)</enum><text>were denied by drug sponsors.</text></subparagraph></paragraph> 
<paragraph id="H61114C8365C9477B8B40346E86FFC2FA"><enum>(7)</enum><text>How to encourage drug sponsors to grant requests for expanded access under such section 561, including requests for emergency use, intermediate-size patient populations, and large patient populations under a specified indication.</text></paragraph> <paragraph id="H67EBCE6028F64478974704857A52F97A"><enum>(8)</enum><text>Whether and to what extent adverse events reported to the Secretary as a result of individual use of an investigational drug or investigational device under such section 561 affected the development or approval of any drug or device.</text></paragraph></section> 
<section id="HE36DD142CD564AE1ACAF88E18E9B13C7"><enum>5.</enum><header>Expanded Access Task Force</header> 
<subsection id="H94CD22B18F6049CB8CB8AFF69F45C6AD"><enum>(a)</enum><header>Establishment</header><text>The Secretary of Health and Human Services shall establish a task force within the Department of Health and Human Services to explore mechanisms for improving the access individual patients have to investigational drugs pursuant to subsection (b) of section 561 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref>), to be known as the <quote>Expanded Access Task Force</quote> (in this section referred to as the <quote>Task Force</quote>). Not later than 90 days after the date on which the Comptroller General of the United States submits the first report required under section 4, the Task Force shall be convened.</text></subsection> <subsection id="H6A83445B63D8410DAECA4DDE107519CA"><enum>(b)</enum><header>Membership</header> <paragraph id="H127801B4465E47C4BAF57745E434274A"><enum>(1)</enum><header>Composition</header><text>The Task Force shall be composed of not more than 13 voting members appointed as follows:</text> 
<subparagraph id="HC5E1C46E38A64608B35CD14046A9F6A6"><enum>(A)</enum><text>One member to serve as Chairman of the Task Force, appointed by the Speaker of the House of Representatives.</text></subparagraph> <subparagraph id="HB37F7DB20F8849D0B1A4210557256FD6"><enum>(B)</enum><text>One representative from the Department of Health and Human Services, appointed by the Secretary of Health and Human Services.</text></subparagraph> 
<subparagraph id="H5E291D4C27D84193ACEF83D0D4668451"><enum>(C)</enum><text>Six representatives appointed by the majority leader of the House of Representatives, in consultation with the minority leader of the House of Representatives, and the chairman and the ranking member of the Committee on Energy and Commerce of the House of Representatives, including—</text> <clause id="H1C17B414C27D4210AC272342A64DDC78"><enum>(i)</enum><text display-inline="yes-display-inline">one current or former representative of the biopharmaceutical industry of not less than 250 full-time employees;</text></clause> 
<clause id="HED015D94EC4A4AA6961E7B82446DD031"><enum>(ii)</enum><text>one representative of a biopharmaceutical company of less than 250 full-time employees;</text></clause> <clause id="H62014521C0BC4597A5A8DC932F821D89"><enum>(iii)</enum><text>one representative of the patient community;</text></clause> 
<clause id="H18D45FD847AE4363A6C4683BBC10B20B"><enum>(iv)</enum><text>one representative of the rare disease patient community;</text></clause> <clause id="H488B53CD2A0E45EC895368F54B6D75DF"><enum>(v)</enum><text>one representative of the health care provider community; and</text></clause> 
<clause id="H5CB13C46C71147279AEBF9A8D00431CD"><enum>(vi)</enum><text>one bioethicist.</text></clause></subparagraph> <subparagraph id="HD5CB2227DE8A4A04A3A25D56B706DDFA"><enum>(D)</enum><text>Five representatives appointed by majority leader of the Senate, in consultation with the minority leader of the Senate, and the chairman and the ranking member of the Committee on Health, Education, Labor and Pensions of the Senate, including—</text> 
<clause id="H232DD7D3DE904BB49AC8E50A24CA1985"><enum>(i)</enum><text display-inline="yes-display-inline">one representative of the biopharmaceutical industry of not less than 250 full-time employees;</text></clause> <clause id="H0867D02D1DD84C19BCFC23D2F2E8BE2A"><enum>(ii)</enum><text>one current or former representative of a biopharmaceutical company of less than 250 full-time employees;</text></clause> 
<clause id="H5D330D9EC0E14099B6B6818BDE265E37"><enum>(iii)</enum><text>one representative of the patient community; </text></clause> <clause id="H0F9EA611DB06405D92F18BA895E413C6"><enum>(iv)</enum><text>one representative of the rare disease patient community; and</text></clause> 
<clause id="HF09318D7592F4055BDB0850CD752B805"><enum>(v)</enum><text>one representative of the health care payor community.</text></clause></subparagraph></paragraph> <paragraph id="HE79144B538764EF6AD7EB377EDAE7B99"><enum>(2)</enum><header>Compensation</header><text>Members of the Task Force shall serve without compensation.</text></paragraph></subsection> 
<subsection id="HBEBF0B0331684FE0BB9819212595D993"><enum>(c)</enum><header>Duties</header><text>The Task Force shall comprehensively evaluate the access individual patients have to investigational drugs pursuant to subsection (b) of section 561 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref>), taking into account—</text> <paragraph id="HE63AC1747F434EE5B7C4C6C0343A57DD"><enum>(1)</enum><text>the unique challenges faced by children with likely fatal diseases for which there is not a comparable or satisfactory alternative therapy available;</text></paragraph> 
<paragraph id="H58062B4F09C549BB83E81E11E6DA20A3"><enum>(2)</enum><text>possible incentives for biopharmaceutical companies and providers to approve requests submitted under such subsection;</text></paragraph> <paragraph id="H14A43CB1CDA249EEBE8F3DE0E01A17AD"><enum>(3)</enum><text>ways to improve followup reporting of adverse event data and compliance with such reporting requirements;</text></paragraph> 
<paragraph id="H84A4C8CD8AD84BE9B7E2F5279215F31C"><enum>(4)</enum><text>how the Secretary of Health and Human Services interprets and takes into consideration adverse event data reported in the case of data from use under a request submitted under such subsection;</text></paragraph> <paragraph id="HCFC75E4D58A242BA93ACEFFC1B669D85"><enum>(5)</enum><text>ways to streamline and standardize the process for submitting requests under such subsection; and</text></paragraph> 
<paragraph id="H4FE756DBD48345F4B592387F880BC949"><enum>(6)</enum><text>the costs incurred by biopharmaceutical companies for the time, effort, and delivery of investigational drugs to patients for the diagnosis, monitoring, or treatment of a serious disease or condition under such subsection.</text></paragraph></subsection> <subsection id="H33964ED8A00A481B80C722F51D3C299B"><enum>(d)</enum><header>Report</header><text>Not later than 180 days after the date on which the Task Force is convened, the Task Force shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor and Pensions of the Senate a report in an electronic format describing the specific recommendations of the Task Force for improving the access individual patients have to investigational drugs pursuant to subsection (b) of section 561 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref>).</text></subsection> 
<subsection id="HA6D9064BAA66458E951A84F54B0AAECA"><enum>(e)</enum><header>Termination</header><text>The task force shall terminate upon submission of the report required under subsection (d).</text></subsection></section> <section id="H02340CA1AD47404DA21FABEE46B8EB4B"><enum>6.</enum><header>Finalizing draft guidance on expanded access</header> <subsection id="HF5B1D28D80BC40E39E0E912A6327A1D7"><enum>(a)</enum><header>In general</header><text>Not later than 180 days after the date on which the Expanded Access Task Force established under section 5 submits the report under subsection (d) of such section, the Secretary of Health and Human Services shall finalize the draft guidance entitled <quote>Expanded Access to Investigational Drugs for Treatment Use—Qs &amp; As</quote> and dated May 2013.</text></subsection> 
<subsection id="HD7B6B407E6C64736A95250462F3BAD56"><enum>(b)</enum><header>Contents</header><text>The final guidance referred to in subsection (a) shall—</text> <paragraph id="HCE8AA46F2DB94F6E988AEEE41BFAFE41"><enum>(1)</enum><text>clearly define how the Secretary interprets and uses adverse drug event data reported by investigators in the case of data reported from use under a request submitted under section 561(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb(b)</external-xref>); and</text></paragraph> 
<paragraph id="H52796B7865F341789FDF340373AEB1B5"><enum>(2)</enum><text>take into account the report of the Expanded Access Task Force submitted under section 5(d) and the first report of the Comptroller General of the United States submitted under section 4.</text></paragraph></subsection></section> </legis-body> </bill> 

